Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 11;8(1):37.
doi: 10.1186/s40942-022-00389-x.

Combined intravitreal injection of bevacizumab and a ROCK inhibitor (fasudil) for refractory macular edema secondary to retinal vein occlusion: a pilot study

Sahba Fekri  1   2 , Ramin Nourinia  3   4 , Babak Rahimi-Ardabili  1 , Arash Daneshtalab  1 , Hamideh Sabbaghi  5   6 , Hamid Ahmadieh  1 , Bahareh Kheiri  1
Affiliations

Combined intravitreal injection of bevacizumab and a ROCK inhibitor (fasudil) for refractory macular edema secondary to retinal vein occlusion: a pilot study

Sahba Fekri et al. Int J Retina Vitreous. .

Abstract

Background: To investigate the adjunctive effect of an intravitreal ROCK inhibitor (fasudil) in combination with intravitreal bevacizumab (IVB) on refractory macular edema secondary to retinal vein occlusion (RVO).

Methods: In this prospective interventional case series, 17 eyes of 17 patients (10 men, 7 women) with refractory RVO-related macular edema underwent three consecutive intravitreal injections of bevacizumab plus fasudil. Monthly evaluation was continued up to 12 months and IVB injection was performed if needed during the follow-up. Changes in the best corrected visual acuity (BCVA) was the primary outcome measure. The secondary outcome measures included central macular thickness (CMT) changes and any adverse events.

Results: BCVA significantly improved (mean change: -0.15 LogMAR; P = 0.017) after 3 consecutive intravitreal injections of fasudil in combination with bevacizumab. CMT significantly decreased (mean change: -206 µm; P = 0.028). The anatomical and functional improvement was maintained during the 12 month follow-up. No adverse effects were noticed.

Conclusion: Intravitreal ROCK inhibitors may break the resistance to anti-VEGF therapy and improve the RVO induced macular edema via affecting the VEGF-independent pathways.

Keywords: Bevacizumab; Fasudil; Macular edema; ROCK inhibitor; Retinal vein occlusion.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Ip M, Hendrick A. Retinal vein occlusion review. Asia-Pacific J Ophthalmol. 2018;7(1):40–45. - PubMed
    1. Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS, Midena E, Sivaprasad S, Tadayoni R, et al. Guidelines for the management of retinal vein occlusion by the European society of retina specialists (EURETINA) Ophthalmologica. 2019;242(3):123–162. doi: 10.1159/000502041. - DOI - PubMed
    1. Nourinia R, Nakao S, Zandi S, Safi S, Hafezi-Moghadam A, Ahmadieh H. ROCK inhibitors for the treatment of ocular diseases. British J Ophthalmol. 2018;102(1):1–5. doi: 10.1136/bjophthalmol-2017-310378. - DOI - PubMed
    1. Ahmadieh H, Nourinia R, Hafezi-Moghadam A. Intravitreal fasudil combined with bevacizumab for persistent diabetic macular edema: a novel treatment. JAMA Ophthalmol. 2013;131(7):923–924. doi: 10.1001/jamaophthalmol.2013.143. - DOI - PubMed
    1. Nourinia R, Ahmadieh H, Shahheidari MH, Zandi S, Nakao S, Hafezi-Moghadam A. Intravitreal fasudil combined with bevacizumab for treatment of refractory diabetic macular edema; a pilot study. J Ophthalmic Vis Res. 2013;8(4):337–340. - PMC - PubMed

LinkOut - more resources